Literature DB >> 31134509

Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.

Yuichi Mitani1, Mitsuteru Hiwatari2, Masafumi Seki1, Mayumi Hangai1, Junko Takita1,3.   

Abstract

Patients with acute myeloid leukemia (AML) co-expressing NUP98/NSD1 and FLT3/ITD have a dismal prognosis despite undergoing hematopoietic stem cell transplantation (HSCT). There are a few studies on successful treatment of relapsed AML co-expressing NUP98/NSD1 and FLT3/ITD. We report a refractory case of molecular relapse of AML co-expressing NUP98/NSD1 and FLT3/ITD post-matched sibling HSCT. Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. Our case suggests the clinical efficacy of preemptive DLI following minimal residual disease analysis for the treatment of refractory AML.

Entities:  

Keywords:  Acute myeloid leukemia; FLT3/ITD; NUP98/NSD1; Peripheral blood stem cell transplantation; Preemptive donor lymphocyte infusions

Mesh：

Substances：

Year:  2019        PMID： 31134509     DOI： 10.1007/s12185-019-02665-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  28 in total

1.  High frequencies of simultaneous FLT3-ITD, WT1 and KIT mutations in hematological malignancies with NUP98-fusion genes.

Authors:  T Taketani; T Taki; T Nakamura; Y Kobayashi; E Ito; S Fukuda; S Yamaguchi; Y Hayashi
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

2.  Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia.

Authors:  Alida Dominietto; Sarah Pozzi; Maurizio Miglino; Flavio Albarracin; Giovanna Piaggio; Francesca Bertolotti; Raffaella Grasso; Simona Zupo; Anna Maria Raiola; Marco Gobbi; Francesco Frassoni; Andrea Bacigalupo
Journal:  Blood       Date:  2007-06-01       Impact factor: 22.113

3.  Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation.

Authors:  Eva Rettinger; Andre M Willasch; Hermann Kreyenberg; Arndt Borkhardt; Wolfgang Holter; Bernhard Kremens; Brigitte Strahm; Wilhelm Woessmann; Christine Mauz-Koerholz; Bernd Gruhn; Stefan Burdach; Michael H Albert; Paul-Gerhardt Schlegel; Thomas Klingebiel; Peter Bader
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

4.  The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.

Authors:  David I Marks; Richard Lush; Jamie Cavenagh; Donald W Milligan; Steven Schey; Anne Parker; Fiona J Clark; Linda Hunt; John Yin; Steven Fuller; Elisabeth Vandenberghe; Judith Marsh; Timothy Littlewood; Graeme M Smith; Dominic Culligan; Ann Hunter; Rajesh Chopra; Andrew Davies; Keiren Towlson; Catherine D Williams
Journal:  Blood       Date:  2002-11-01       Impact factor: 22.113

5.  Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.

Authors:  S Shiobara; S Nakao; M Ueda; H Yamazaki; S Takahashi; S Asano; H Yabe; S Kato; S Imoto; A Maruta; T Yoshida; H Gondo; Y Morishima; Y Kodera
Journal:  Bone Marrow Transplant       Date:  2000-10       Impact factor: 5.483

6.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.

Authors:  F Dazzi; R M Szydlo; C Craddock; N C Cross; J Kaeda; A Chase; E Olavarria; F van Rhee; E Kanfer; J F Apperley; J M Goldman
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

7.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

Authors:  Bruce D Cheson; John M Bennett; Kenneth J Kopecky; Thomas Büchner; Cheryl L Willman; Elihu H Estey; Charles A Schiffer; Hartmut Doehner; Martin S Tallman; T Andrew Lister; Francesco Lo-Coco; Roel Willemze; Andrea Biondi; Wolfgang Hiddemann; Richard A Larson; Bob Löwenberg; Miguel A Sanz; David R Head; Ryuzo Ohno; Clara D Bloomfield; Francesco LoCocco
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544

8.  Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose.

Authors:  Cesare Guglielmi; William Arcese; Francesco Dazzi; Ronald Brand; Donald Bunjes; Leo F Verdonck; Anton Schattenberg; Hans-Jochem Kolb; Per Ljungman; Agnes Devergie; Andrea Bacigalupo; Marta Gomez; Mauricette Michallet; Ahmet Elmaagacli; Alois Gratwohl; Jane Apperley; Dietger Niederwieser
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

10.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.

Authors:  Christoph Schmid; Myriam Labopin; Arnon Nagler; Martin Bornhäuser; Jürgen Finke; Athanasios Fassas; Liisa Volin; Günham Gürman; Johan Maertens; Pierre Bordigoni; Ernst Holler; Gerhard Ehninger; Emmanuelle Polge; Norbert-Claude Gorin; Hans-Jochem Kolb; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2007-10-01       Impact factor: 44.544
View more
  1 in total

1.  The First Korean Case of NUP98-NSD1 and a Novel SNRK-ETV6 Fusion in a Pediatric Therapy-related Acute Myeloid Leukemia Patient Detected by Targeted RNA Sequencing.

Authors:  Ha Jin Lim; Jun Hyung Lee; Young Eun Lee; Hee-Jo Baek; Hoon Kook; Ju Heon Park; Seung Yeob Lee; Hyun-Woo Choi; Hyun-Jung Choi; Seung-Jung Kee; Jong Hee Shin; Myung Geun Shin
Journal:  Ann Lab Med       Date:  2021-07-01       Impact factor: 3.464
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.